Apremilast in the Treatment of Psoriasis and Psoriatic Arthritis.

Apremilast in the Treatment of Psoriasis and Psoriatic Arthritis. Skin Therapy Lett. 2015 Sep;20(5):1-6 Authors: Gooderham M, Papp K Abstract Phosphodiesterase 4 (PDE4) is a key enzyme in the regulation of immune responses of inflammatory diseases through degradation of the second messenger, cyclic adenosine 3',5'-monophosphate (cAMP). Apremilast, a selective PDE4 inhibitor, has been shown to reduce the production of pro-inflammatory cytokines by increasing intracellular levels of cAMP and promoting the production of anti-inflammatory cytokines. The efficacy and safety of apremilast in the treatment of psoriasis and psoriatic arthritis has been demonstrated in phase 2 and 3 studies and will be reviewed here. Across all studies, treatment was generally well-tolerated with some mild gastrointestinal complaints that occurred early and resolved over time, resulting in few drop-outs. Meaningful changes in dactylitis and enthesitis were also observed. Routine monitoring is not required given the absence of drug associated physiologic, biochemical, and haematological changes. Apremilast proves to be a new promising systemic therapy for treating psoriatic disease. PMID: 26382906 [PubMed - in process]
Source: Skin Therapy Letter - Category: Dermatology Authors: Tags: Skin Therapy Lett Source Type: research

Related Links:

Publication date: Available online 15 November 2019Source: Autoimmunity ReviewsAuthor(s): José María G. Ruiz de Morales, Lluís Puig, Esteban Daudén, Juan D. Cañete, José Luis Pablos, Antonio Olveira Martín, Carlos González Juanatey, Alfredo Adán, Xavier Montalbán, Natalia Borruel, Guillermo Ortí, Esther Holgado Martín, Carolina García-Vidal, Cynthia Vizcaya Morales, Víctor Martín Vázquez, Miguel Ángel González-GayAbstractInterleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of...
Source: Autoimmunity Reviews - Category: Allergy & Immunology Source Type: research
In conclusion, the PEST-bp questionnaire proved to be suitable as a screening tool for PsA in patients with psoriasis. Elevated PEST-bp scores are associated with decreased patient quality of life.
Source: Archives of Dermatological Research - Category: Dermatology Source Type: research
TUESDAY, Nov. 12, 2019 -- For patients with psoriatic arthritis (PsA), the age of psoriasis onset determines whether arthritis or psoriasis starts first, according to a study presented at the annual meeting of the American College of Rheumatology,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
ConclusionsSecukinumab appears to be cost effective compared with other DMARDs for the treatment of active PsA in biologic-na ïve and biologic-experienced populations in Germany.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
Authors: Bakewell C, Aydin SZ, Ranganath VK, Eder L, Kaeley GS Abstract Psoriatic arthritis (PsA) affects up to 30% of patients with psoriasis and may include musculoskeletal manifestations such as enthesitis. Enthesitis is associated with joint damage, and early detection and treatment are essential to management of the disease. Traditionally assessed by clinical examination and conventional radiography, entheseal inflammation can now be more accurately assessed earlier in the disease using techniques such as ultrasound, magnetic resonance imaging, computed tomography, and molecular imaging. However, there is litt...
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
Authors: Haddad A, Feld J, Zisman D Abstract Several screening questionnaires have been developed to identify patients with psoriatic arthritis (PsA) in the psoriasis population in dermatology and general practice settings1,2,3,4,5 However, the diagnosis of PsA using these questionnaires is a topic for debate, partly because of disease heterogeneity, and the complications from inconsistent performance results6,7,8,9. PMID: 31676694 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
It is impossible to know who will develop psoriatic arthritis, though it usually affects people who already have psoriasis. Learn about whether people can prevent psoriatic arthritis here.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news
Authors: Lubrano E, Scriffignano S, Perrotta FM Abstract Introduction: Psoriatic Arthritis (PsA) is a chronic inflammatory disease characterized by psoriasis, synovitis, enthesitis, spondylitis and association with extra-articular manifestations and comorbidities. Treatment of PsA dramatically changed since the introduction of anti-TNF drugs which have shown to reduce the symptoms and signs of the disease and slow the radiographic progression. Despite the introduction of new molecules with different mechanisms of action, the role of anti-TNF in the treatment of all disease manifestations of this intriguing disease ...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
ConclusionsOverall, in this study with more than 70% of patients with moderate disease, patients reported high burden of disease and impact on QoL. This study demonstrates the importance of considering patient perspectives in treatment decisions that are critical for optimizing patient outcomes.FundingEli Lilly and Company.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
We report four cases of extensive AA successfully treated with apremilast.
Source: International Journal of Trichology - Category: Dermatology Authors: Source Type: research
More News: Arthritis | Dermatology | Gastroenterology | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin | Study